Skip to Main Content

A pretty impressive result from ASCO that’s also being published in the New England Journal of Medicine: Kisqali, a breast cancer drug from Novartis (NVS), dramatically extended survival in younger women who developed the most common form of breast cancer.

In women with hormone receptor positive/HER2 negative breast cancer who were premenopausal, adding Kisqali to hormone-blocking therapy resulted in a 29% reduction in the risk of death. After three and a half years, that translates into 70% of the women who got the combination being alive, compared to 42% of those who got the standard therapy. That’s a dramatic improvement in a disease where it is often hard to prove a survival benefit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!